Literature DB >> 17096683

Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects.

Jae-Gook Shin1, Won-Ku Kang, Ji-Hong Shon, Million Arefayene, Young-Ran Yoon, Kyung-Ah Kim, Doo-Il Kim, Dong-Soo Kim, Kwang-Hyun Cho, Raymond L Woosley, David A Flockhart.   

Abstract

AIMS: The aim of this study was to evaluate the pharmacokinetics and pharmacodynamics of quinidine-induced QT prolongation in healthy Caucasian and Korean subjects to investigate interethnic differences in susceptibility to drug-induced arrhythmia.
METHODS: A randomized, double-blind crossover study was conducted in 24 (12 male and 12 female) Korean and 13 (seven male and six female) Caucasian subjects. After a 20 min infusion of quinidine (4 mg kg(-1)) or saline, the serum concentration of quinidine and the QT interval corrected by Bazett's formula (QTc) were monitored. The dynamic data were analyzed by means of a population modelling approach using NONMEM.
RESULTS: There were no statistical differences in the pharmacokinetic profiles of quinidine between ethnic groups. The QTc values in Caucasians were higher than those in Koreans at the same quinidine concentrations, especially at higher quinidine concentrations and in female subjects. According to an E(max) model [equation: see text], the population modelling approach revealed that E0 (ms) was related to gender (408 + [34*(1 - Sex)]; 1 for male and 0 for female), DeltaE(max) (ms) was related to ethnicity ((136*f(ETHN)) + C(female): f(ETHN) = 1 for Koreans and 1.26 for Caucasians; C(female) was 106 only for Caucasian females), and EC50 was estimated to be 3.13 microm.
CONCLUSIONS: These results suggest that Korean subjects were less sensitive to quinidine-induced QT prolongation than Caucasian subjects, and that this trend was particularly true for females. Further population-based studies are merited to characterize more completely the ethnic differences in drug-induced QT prolongation between Asians and other ethnic groups.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17096683      PMCID: PMC2000575          DOI: 10.1111/j.1365-2125.2006.02793.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  32 in total

1.  The electrocardiographic effects of cetirizine in normal subjects.

Authors:  M E Sale; J T Barbey; R L Woosley; D Edwards; J Yeh; K Thakker; M Chung
Journal:  Clin Pharmacol Ther       Date:  1994-09       Impact factor: 6.875

Review 2.  Class I antiarrhythmic agents: quinidine, procainamide and N-acetylprocainamide, disopyramide.

Authors:  D M Roden; R L Woosley
Journal:  Pharmacol Ther       Date:  1983       Impact factor: 12.310

Review 3.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

4.  Blood quinidine levels and cardiac effects in white British and Nigerian subjects.

Authors:  A Olatunde; D A Price Evans
Journal:  Br J Clin Pharmacol       Date:  1982-10       Impact factor: 4.335

5.  Electrocardiographic quantitation of ventricular repolarization.

Authors:  M Merri; J Benhorin; M Alberti; E Locati; A J Moss
Journal:  Circulation       Date:  1989-11       Impact factor: 29.690

6.  Characterization of a novel Long QT syndrome mutation G52R-KCNE1 in a Chinese family.

Authors:  Lijuan Ma; Chunxia Lin; Siyong Teng; Yongping Chai; Robert Bähring; Vitya Vardanyan; Liang Li; Olaf Pongs; Rutai Hui
Journal:  Cardiovasc Res       Date:  2003-09-01       Impact factor: 10.787

7.  Sex differences in the evolution of the electrocardiographic QT interval with age.

Authors:  P M Rautaharju; S H Zhou; S Wong; H P Calhoun; G S Berenson; R Prineas; A Davignon
Journal:  Can J Cardiol       Date:  1992-09       Impact factor: 5.223

8.  Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care.

Authors:  D M Roden; R L Woosley; R K Primm
Journal:  Am Heart J       Date:  1986-06       Impact factor: 4.749

Review 9.  QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs.

Authors:  Luigi X Cubeddu
Journal:  Am J Ther       Date:  2003 Nov-Dec       Impact factor: 2.688

10.  Early repolarization on scalar electrocardiogram.

Authors:  M C Mehta; A C Jain
Journal:  Am J Med Sci       Date:  1995-06       Impact factor: 2.378

View more
  14 in total

1.  Comparison of the effects of levofloxacin on QT/QTc interval assessed in both healthy Japanese and Caucasian subjects (pages.

Authors:  Atsushi Sugiyama; Yuji Nakamura; Satomi Nishimura; Satomi Adachi-Akahane; Yuji Kumagai; Juleen Gayed; Asif Naseem; Georg Ferber; Jorg Taubel; John Camm
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

2.  Adverse drug reactions--no farewell to harms.

Authors:  Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2007-02       Impact factor: 4.335

Review 3.  The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance.

Authors:  Borje Darpo
Journal:  Br J Pharmacol       Date:  2009-11-18       Impact factor: 8.739

Review 4.  Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

5.  Moxifloxacin-induced QTc interval prolongations in healthy male Japanese and Caucasian volunteers: a direct comparison in a thorough QT study.

Authors:  Joel Morganroth; Yaning Wang; Michael Thorn; Yuji Kumagai; Stuart Harris; Norman Stockbridge; Robert Kleiman; Rashmi Shah
Journal:  Br J Clin Pharmacol       Date:  2015-07-02       Impact factor: 4.335

6.  Prevalence and Correlates of Electrocardiographic Abnormalities in Adults With HIV: Insights From the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).

Authors:  Gerald S Bloomfield; Isabelle R Weir; Heather J Ribaudo; Kathleen V Fitch; Carl J Fichtenbaum; Laura E Moran; Roger Bedimo; Christopher de Filippi; Caryn G Morse; Jonathan Piccini; Markella V Zanni; Michael T Lu; Udo Hoffmann; Steven K Grinspoon; Pamela S Douglas
Journal:  J Acquir Immune Defic Syndr       Date:  2022-03-01       Impact factor: 3.771

7.  Genetic polymorphism of glutathione S-transferase T1 (GSTT1) and QT-interval in schizophrenia patients.

Authors:  Aminollah Bahaoddini; Hassan Farrashbandi; Mostafa Saadat
Journal:  J Mol Neurosci       Date:  2009-01-16       Impact factor: 3.444

8.  Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalol.

Authors:  Borje Darpo; Dilip R Karnad; Fabio Badilini; Jeff Florian; Christine E Garnett; Snehal Kothari; Gopi Krishna Panicker; Nenad Sarapa
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

9.  Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects.

Authors:  Taegon Hong; Seunghoon Han; Jongtae Lee; Sangil Jeon; Gab-Jin Park; Wan-Su Park; Kyoung Soo Lim; Jae-Yong Chung; Kyung-Sang Yu; Dong-Seok Yim
Journal:  Drug Des Devel Ther       Date:  2015-02-26       Impact factor: 4.162

10.  Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects.

Authors:  Yuji Kumagai; Tomoko Hasunuma; Soichi Sakai; Hidekazu Ochiai; Yoshishige Samukawa
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.